Mechanism of Folding and Binding of the N-Terminal SH2 Domain from SHP2.
暂无分享,去创建一个
M. Brunori | S. Gianni | Daniela Bonetti | A. Toto | Maurizio Brunori | Stefano Gianni | Carlo Travaglini-Allocatelli | Angelo Toto | Daniela Bonetti | Francesca Troilo | Francesca Troilo | C. Travaglini-Allocatelli
[1] C. Pace,et al. Denaturant m values and heat capacity changes: Relation to changes in accessible surface areas of protein unfolding , 1995, Protein science : a publication of the Protein Society.
[2] L. Mei,et al. Requirement of SHP2 Binding to Grb2-associated Binder-1 for Mitogen-activated Protein Kinase Activation in Response to Lysophosphatidic Acid and Epidermal Growth Factor* , 2000, The Journal of Biological Chemistry.
[3] A. Heck,et al. Protein Flexibility and Ligand Rigidity: A Thermodynamic and Kinetic Study of ITAM‐Based Ligand Binding to Syk Tandem SH2 , 2005, Chembiochem : a European journal of chemical biology.
[4] S. Pillai,et al. Sialic acids and autoimmune disease , 2016, Immunological reviews.
[5] Hongyang Wang,et al. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis , 2012, Frontiers of Medicine.
[6] Sheena E. Radford,et al. Im7 folding mechanism: misfolding on a path to the native state , 2002, Nature Structural Biology.
[7] Bruce J Mayer,et al. What Have We Learned from SH2 Domains? , 2017, Methods in molecular biology.
[8] A. Fersht,et al. Folding of chymotrypsin inhibitor 2. 1. Evidence for a two-state transition. , 1991, Biochemistry.
[9] P. Jemth,et al. A conserved folding mechanism for PDZ domains , 2007, FEBS letters.
[10] C. Walsh,et al. The phosphopeptide-binding specificity of Src family SH2 domains. , 1994, Chemistry & biology.
[11] R. Nussinov,et al. Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH2 Domains. , 2017, Biophysical journal.
[12] Andreas Matouschek,et al. Transient folding intermediates characterized by protein engineering , 1990, Nature.
[13] Sheena E. Radford,et al. Ultrarapid mixing experiments reveal that Im7 folds via an on-pathway intermediate , 2001, Nature Structural Biology.
[14] D. Baltimore,et al. Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides , 1993, Nature.
[15] K. Jeng,et al. Effects of peptidic antagonists of Grb2-SH2 on human breast cancer cells. , 2010, Protein and peptide letters.
[16] S. Khorasanizadeh,et al. Evidence for a three-state model of protein folding from kinetic analysis of ubiquitin variants with altered core residues , 1996, Nature Structural Biology.
[17] M. Brunori,et al. Identification and characterization of protein folding intermediates. , 2007, Biophysical chemistry.
[18] John S McMurray,et al. Targeting SH2 domains in breast cancer. , 2014, Future medicinal chemistry.
[19] S. Radford,et al. Rapid folding with and without populated intermediates in the homologous four-helix proteins Im7 and Im9. , 1999, Journal of molecular biology.
[20] P. Jemth,et al. Ligand binding by PDZ domains , 2012, BioFactors.
[21] S. Marqusee,et al. Native state energetics of the Src SH2 domain: Evidence for a partially structured state in the denatured ensemble , 2006, Protein science : a publication of the Protein Society.
[22] M. J. Parker,et al. An integrated kinetic analysis of intermediates and transition states in protein folding reactions. , 1995, Journal of molecular biology.